Production underway on a new weapon to fight ovarian cancer

With one woman in Australia dying every eight hours from ovarian cancer, the urgency to address the unmet clinical need in cancer therapeutics has never been more paramount. A significant manufacturing agreement between OncoTEX Inc. (OncoTEX) and Sterling Pharma Solutions will see the production of novel platinum-resistant cancer-fighting drug, OxaliTEX, scaled up for preclinical and […]

More

GBS, Inc. receives approval to commence validation clinical study for rapid SARS-CoV-2 diagnostic test

NEW YORK APRIL 15, 2021 — GBS, Inc. (GBS), a life sciences company developing non-invasive, real-time point-of-care (POC) diagnostic tests, and the Wyss Institute for Biologically Inspired Engineering at Harvard University (Wyss Institute) have received approval from the Harvard Longwood campus Institutional Review Board (IRB) to commence a validation study to test clinical samples from […]

More

The iQ Group Global celebrates 10 years of innovation

Today marks a major milestone for The iQ Group Global with its 10th anniversary. What started as a bold vision to accelerate medical innovation by CEO and founder Dr George Syrmalis in 2011, has evolved into an internationally recognised bioscience investment consortium, championing a portfolio of world-first innovations in the fields of diagnostics and oncology. […]

More

GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Development of Saliva-Based Diagnostic Tests

New York, NY, February 18, 2021 – GBS Inc. (Nasdaq: GBS), a life sciences company that develops non-invasive, real-time point of care (POC) diagnostic tests for patients and their primary health practitioners, today announced the execution of a sponsored research agreement with Johns Hopkins Bloomberg School of Public Health to accelerate development of next-generation saliva-based diagnostic tests. […]

More

Harvard’s Wyss Institute collaborates with GBS Inc. on the Wyss’ eRapid-based COVID-19 diagnostic to help curb the pandemic

Combination of the Wyss’ electrochemical sensing technology with GBS’s transistor technology could enable fast, multiplexed, low-cost COVID-19 biomarker analysis in point-of-care applications. This article has been republished with permission from the Wyss Institute at Harvard University. Click here to view the original article. By Benjamin Boettner (BOSTON) — The Wyss Institute for Biologically Inspired Engineering at Harvard […]

More

Harvard’s Wyss Institute licenses its eRapid technology to The iQ Group Global to accelerate the development of COVID-19 diagnostics

The low-cost electrochemical technology for multiplexed biomarker detection could facilitate global serological testing for SARS-CoV-2 infections, and help trace immunity in individuals over time. This article has been republished with permission from the Wyss Institute at Harvard University. Click here to view the original article. By Benjamin Boettner (BOSTON) — Today, the Wyss Institute for […]

More